Literature DB >> 18001932

High power phased array prototype for clinical high intensity focused ultrasound : applications to transcostal and transcranial therapy.

M Pernot1, J -F Aubry, M Tanter, F Marquet, G Montaldo, A -L Boch, M Kujas, D Seilhean, M Fink.   

Abstract

Bursts of focused ultrasound energy three orders of magnitude more intense than diagnostic ultrasound became during the last decade a noninvasive option for treating cancer from breast to prostate or uterine fibroid. However, many challenges remain to be addressed. First, the corrections of distortions induced on the ultrasonic therapy beam during its propagation through defocusing obstacles like skull bone or ribs remain today a technological performance that still need to be validated clinically. Secondly, the problem of motion artifacts particularly important for the treatment of abdominal parts becomes today an important research topic. Finally, the problem of the treatment monitoring is a wide subject of interest in the growing HIFU community. For all these issues, the potential of new ultrasonic therapy devices able to work both in Transmit and Receive modes will be emphasized. A review of the work under achievement at L.O.A. using this new generation of HIFU prototypes on the monitoring, motion correction and aberrations corrections will be presented.

Entities:  

Mesh:

Year:  2007        PMID: 18001932     DOI: 10.1109/IEMBS.2007.4352266

Source DB:  PubMed          Journal:  Annu Int Conf IEEE Eng Med Biol Soc        ISSN: 2375-7477


  2 in total

1.  High-intensity focused ultrasound with large scale spherical phased array for the ablation of deep tumors.

Authors:  Xiang Ji; Jing-feng Bai; Guo-feng Shen; Ya-zhu Chen
Journal:  J Zhejiang Univ Sci B       Date:  2009-09       Impact factor: 3.066

Review 2.  Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed.

Authors:  F M Gómez; J Palussière; E Santos; T Tourdias; F Cornélis; V Sáiz; H Montes; O Eker
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.